Cross-sectional imaging can be used to monitor response to corticosteroid treatment.
The ability to monitor response to therapy for tuberculosis (TB) and confirm adequate treatment would be a major advance.
A specific questionnaire (PedMIDAS) provides a tool to assess the impact of migraines in children and to monitor response to treatment.
Diagnostic somatostatin radiotracers, such as the ones evaluated in this study, can identify breast cancer lesions and monitor response to therapy by PRRT.
Collectively, these data show that 111In-bevacizumab is a specific radiotracer to visualise VEGF within tumours and monitor response to anti-angiogenic therapy mediated by mTOR inhibition.
Consistent with this, prior studies have reported that EVLWI measurements can be successfully used to monitor response to β agonist therapy [39, 40].
As there is no clinical sign for immunosuppression, biomarkers are needed in order to both include patients and ideally to monitor response to treatment [2].
Detection of this mutation aids diagnosis of these neoplasms, and quantification of JAK2 V617F may provide a method to monitor response to therapy.
For cancer treatment, the most promising clinical use of SCS is the analysis of CTCs, which may provide a non-invasive method for clinicians to monitor response to therapy before tumors become symptomatic or detectable through traditional approaches.
The main purpose of the study was to identify image registration strategies that can serve as candidates for registration of repeat [18F]FDG PET scans in order to monitor response to treatment.
As with all cancer therapies, anti-angiogenic therapy is only effective in a subgroup of patients and hence there is a need to develop new methods to predict and monitor response to treatment.
